Janux Therapeutics, Inc.
JANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,877,854 | $472,295 | $546,155 | $813,727 |
| - Cash | $430,605 | $19,205 | $51,426 | $35,582 |
| + Debt | $23,025 | $24,542 | $25,305 | $194 |
| Enterprise Value | $2,470,274 | $477,632 | $520,034 | $778,339 |
| Revenue | $10,588 | $8,083 | $8,612 | $3,637 |
| % Growth | 31% | -6.1% | 136.8% | – |
| Gross Profit | $8,528 | $6,128 | $7,771 | $3,637 |
| % Margin | 80.5% | 75.8% | 90.2% | 100% |
| EBITDA | -$96,787 | -$71,024 | -$66,250 | -$32,816 |
| % Margin | -914.1% | -878.7% | -769.3% | -902.3% |
| Net Income | -$68,994 | -$58,293 | -$63,059 | -$32,672 |
| % Margin | -651.6% | -721.2% | -732.2% | -898.3% |
| EPS Diluted | -1.28 | -1.32 | -1.52 | -0.79 |
| % Growth | 3% | 13.2% | -92.4% | – |
| Operating Cash Flow | -$43,814 | -$50,575 | -$42,922 | -$16,976 |
| Capital Expenditures | -$359 | -$1,850 | -$6,445 | -$1,482 |
| Free Cash Flow | -$44,173 | -$52,425 | -$49,367 | -$18,458 |